In addition, an in vitro study by Toyoda et al. demonstrated how FGF2, secreted by GBM cells, can improve blood–tumor barrier functionality, contributing to the typical GBM refractoriness to therapies [146]. This evidence concerns the gene FGF2 and glioblastoma.